Bambusa, Aspen, and Tang added to IPO pipeline
2026's sizeable haul of IPOs shows no signs of letting up, with three more biotechs – Bambusa, Aspen, and blank cheque firm Tang – joining the queue.
Syndax shares fall as lung fibrosis drug fails trial
Syndax shares lost 17% of their value pre-market after the company said it abandoned development of axatilimab for idiopathic pulmonary fibrosis.
Females with autoimmune disease 'less likely to be believed'
Women and girls with autoimmune diseases are more likely to have their condition misdiagnosed as psychiatric or psychosomatic than males, study finds.
Brent Saunders ejects from Bausch + Lomb once again
Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end.
BMS eyes filings for idiopathic pulmonary fibrosis drug
Bristol Myers Squibb has reported phase 3 results with a new drug for idiopathic pulmonary fibrosis that could open the door to regulatory filings.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
Oncology
Patients
R&D
Partner Content
UAE investment drives Middle East biopharma transformation a...
Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in the Middle East over the ne
Europe's Largest Gathering for ADC Innovation
Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community
PharmaMarketing Summit 2027 to Convene America's Top Pharmac...
Elite industry leaders will gather to address AI-driven engagement, launch excellence, and the future of market access at an exclusive, invitation-only event
3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...
The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across companies to share data-driven insights
CPHI Milan 2026 showcases new Sustainability Summit
The first-time event will bring delegates together to discuss sustainability challenges